Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free APTO Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Aptose Biosciences (APTO) Competitors

Aptose Biosciences logo
Compare

APTO vs. FNCH, ZIVO, NKGN, SQZ, and SRNE

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Finch Therapeutics Group (FNCH), ZIVO Bioscience (ZIVO), NKGen Biotech (NKGN), SQZ Biotechnologies (SQZ), and Sorrento Therapeutics (SRNE). These companies are all part of the "biological products, except diagnostic" industry.

How does Aptose Biosciences compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Aptose BiosciencesN/AN/A-$51.21M-$89.19N/A

Finch Therapeutics Group's return on equity of -69.14% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Aptose Biosciences N/A -5,683.22%-300.44%

In the previous week, Aptose Biosciences had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Aptose Biosciences Neutral

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Finch Therapeutics Group beats Aptose Biosciences on 5 of the 9 factors compared between the two stocks.

How does Aptose Biosciences compare to ZIVO Bioscience?

Aptose Biosciences (NASDAQ:APTO) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Aptose Biosciences had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for ZIVO Bioscience. Aptose Biosciences' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
ZIVO Bioscience Neutral

Aptose Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.

26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 1.3% of Aptose Biosciences shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ZIVO Bioscience has higher revenue and earnings than Aptose Biosciences. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-$51.21M-$89.19N/A
ZIVO Bioscience$15.85K1,073.09-$7.78M-$2.18N/A

ZIVO Bioscience's return on equity of 0.00% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A -5,683.22% -300.44%
ZIVO Bioscience N/A N/A -2,240.92%

Summary

Aptose Biosciences and ZIVO Bioscience tied by winning 5 of the 10 factors compared between the two stocks.

How does Aptose Biosciences compare to NKGen Biotech?

Aptose Biosciences (NASDAQ:APTO) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Aptose Biosciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

In the previous week, Aptose Biosciences had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for NKGen Biotech. Aptose Biosciences' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
NKGen Biotech Neutral

NKGen Biotech is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-$51.21M-$89.19N/A
NKGen BiotechN/AN/A-$82.94M-$1.51N/A

26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 1.3% of Aptose Biosciences shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NKGen Biotech's return on equity of 0.00% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A -5,683.22% -300.44%
NKGen Biotech N/A N/A -479.36%

Summary

NKGen Biotech beats Aptose Biosciences on 5 of the 9 factors compared between the two stocks.

How does Aptose Biosciences compare to SQZ Biotechnologies?

Aptose Biosciences (NASDAQ:APTO) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Aptose Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

In the previous week, Aptose Biosciences had 2 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for SQZ Biotechnologies. Aptose Biosciences' average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
SQZ Biotechnologies Neutral

Aptose Biosciences has higher earnings, but lower revenue than SQZ Biotechnologies. Aptose Biosciences is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-$51.21M-$89.19N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 1.3% of Aptose Biosciences shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aptose Biosciences has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A -5,683.22% -300.44%
SQZ Biotechnologies -369.96%-119.83%-59.90%

Summary

SQZ Biotechnologies beats Aptose Biosciences on 8 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Sorrento Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Aptose Biosciences has lower revenue, but higher earnings than Sorrento Therapeutics. Aptose Biosciences is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.43N/A
Aptose BiosciencesN/AN/A-$51.21M-$89.19N/A

Sorrento Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Sorrento Therapeutics' return on equity of 0.00% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Aptose Biosciences N/A -5,683.22%-300.44%

In the previous week, Aptose Biosciences had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Aptose Biosciences Neutral

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sorrento Therapeutics beats Aptose Biosciences on 6 of the 10 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTO vs. The Competition

Export
MetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.66M$328.15M$6.24B$11.86B
Dividend YieldN/AN/A2.73%5.21%
P/E Ratio-0.58N/A29.0428.48
Price / SalesN/A189.48477.1060.43
Price / CashN/A22.4427.6236.52
Price / Book-9.004.739.676.67
Net Income-$51.21M-$132.96M$3.55B$332.64M

Aptose Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APTO
Aptose Biosciences
N/A$1.71
flat		N/AN/A$3.66MN/AN/A31
FNCH
Finch Therapeutics Group
N/A$7.66
+3.5%		N/AN/A$12.30MN/AN/A190
ZIVO
ZIVO Bioscience
N/A$2.07
+48.9%		N/AN/A$8.28M$15.85KN/A10
NKGN
NKGen Biotech
N/A$0.06
flat		N/AN/A$7.84MN/AN/AN/A
SQZ
SQZ Biotechnologies
N/A$0.02
-0.4%		N/AN/A$708K$18.16MN/A1,620

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:APTO) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel